CD274 and neoplasm: The current FDA-approved indications are for treatment of patients with locally advanced or metastatic disease who are (A) ineligible for cisplatin-based therapy and have biochemical evidence of >5% PD-L1 expression within the tumor, or (B) ineligible for any platinum-based therapy.